3 Houston innovators to know this week

Who's who

From health care to politics, here's who you need to know in Houston innovation this week. Courtesy photos

There's no summer slowdown in sight, as Houston's innovation world keeps turning. Texas Children's Hospital is amping up their attention to innovation — and so is the mayor. Meanwhile, a local software company just made a big hire. Here's what innovators you need to keep an eye on.

Myra Davis, senior vice president and chief information and innovation officer of Texas Children's Hospital

Myra Davis is responsible for Texas Children's Hospital's technology and innovation — two completely separate things, she says. Courtesy of TCH

Myra Davis wants you to realize that there's a difference between technology and innovation. As the chief information officer, she's been in charge of maintaining tech within the hospital system. However, her role has evolved to include innovation, which means thinking about what new elements TCH can bring in — or what existing elements can be improved or expanded. Read more about Davis and what TCH is up to.

Talin Bingham, CTO of Identity Automation

Talin Bingham has been named CTO of Houston-based Identity Automation. Courtesy of Identity Automation

The chief technology officer is a huge role when it comes to a software company's hierarchy. Houston-based Identity Automation just tasked Talin Bingham with the position. Bingham replaces co-founder Troy Moreland as CTO, and Moreland will support the company in an advisory capacity. Last summer, the company made a major acquisition and sees plenty of opportunities for growth. Read more about the new hire.

Mayor Sylvester Turner

Mayor Sylvester Turner gave his State of the City address on May 20. Natalie Harms/InnovationMap

Mayor Sylvester Turner and his team are innovators themselves, constantly coming up with new ideas to enhance and connect the city. The city's latest endeavor was announced last week at the Greater Houston Partnership's State of the City luncheon. Mayor Turner's idea is to have 50 corporations sponsor 50 Houston-area parks scattered across the city for five years. Up next is finding 49 more companies, since Scott McClelland of HEB offered up his company on the spot. Read the 5 things the mayor promised in the address.

Talin Bingham has been named CTO of Houston-based Identity Automation. Courtesy of Identity Automation

Houston software company hires new CTO after Q1 growth

Mover and shaker

Houston-based Identity Automation has named a new chief technology officer following growth last quarter.

Talin Bingham will replace co-founder Troy Moreland as CTO, and Moreland will support the company in an advisory capacity, according to a release.

"We are excited about the experience and wisdom that Talin brings to this role," says James Litton, CEO at Identity Automation, in the release.

"Talin is a seasoned CTO with an exceptional track record in on-time product delivery and implementation—both of which are essential to the Identity Automation 2.0 growth strategy. We are confident that his entrepreneurial spirit will help us achieve our vision of continued product evolution and rapid expansion across key markets."

Bingham has over 35 years of technical leadership — 25 of which has been in managerial roles. Prior to this appointment, he was the managing director of product and technology at Vista Consulting Group in Utah.

Identity Automation is the provider of RapidIdentity, which is a technology integration platform companies can use to accelerate the digital transformation process. The company has a global presence with tens of millions of identities in its system, which functions both on the premises and cloud resources.

Last summer, the company made its second acquisition — an enterprise single sign-on and virtual desktop platform called HealthCast Inc.

"Identity Automation has the most powerful and scalable platform in the identity management space, backed by a strong leadership team and the momentum of our recent success." Bingham says in the release.

"I'm excited to have a hand in the company's direction during such a pivotal time, ensuring we maximize the quality and delivery of engineering and do so as a cohesive, company-wide effort that make it possible to meet our full potential for growth."

James Litton Discusses Cybersecuritywww.youtube.com

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston researchers develop dissolvable implant for targeted cancer drug delivery

cancer research

Researchers at Houston Methodist have developed a biodegradable implant that can be used to safely and consistently deliver drug treatments to tumors and then dissolve without the need for further surgery.

The implant is only the size of a grain of rice, but its potential is staggering. The biodegradable nanofibrous drug-eluting seed (b-NDES) works as a reservoir parked inside a soft tumor, where it can slowly release immune-stimulating drugs over time. This overcomes a consistent problem with drugs such as immune checkpoint inhibitors. Normal systemic administration sees comparatively little of the drug making its way to the tumor, with most of it circulating throughout the body. The b-NDES is like deploying a small guerrilla fighting force embedded in enemy territory, doing maximum damage to the entrenched tumor.

"To improve cancer treatment, we're trying to start a fire inside the tumor itself," Corrine Chua, associate professor in the Center for BioNanoengineering at Houston Methodist Research Institute, said in a news release. "By activating immune cells directly within the tumor microenvironment, those cells can then travel throughout the body and seek out cancer wherever it exists. The b-NDES platform was developed to help keep therapeutic drugs concentrated inside tumors while minimizing exposure to healthy tissues.”

Chua co-led the study with Alessandro Grattoni, chair and director of the Center for BioNanoengineering at Houston Methodist Research Institute.

The study included support from the Nancy Owens Breast Cancer Foundation and the National Institutes of Health/National Cancer Institute.

Chau and Grattoni used preclinical models of triple-negative breast cancer, an aggressive form of cancer that is estrogen receptor-negative, progesterone receptor-negative and HER2-negative. Because of the receptor negativity, some popular treatments like tamoxifen and trastuzumab are ineffective. Chemotherapy has been shown to be the best course of action.

The b-NDES implant is deployed alongside radiation drugs. It keeps the drugs focused on the tumor, reducing the amount of harmful side effects typically seen when drugs are circulated more widely in the body. In 60 percent of the models, tumors were eliminated and did not cause side effects beyond the tumor site. Once the drugs have been deployed, the implant breaks down naturally.

While promising, more research will have to be done to expand use to other tumor types.

"Although the study focused on triple-negative breast cancer models, the approach could have broader applications for solid tumors," Grattoni added in the release. "It could potentially be used in cancers where there is a tumor lesion accessible for placement, including pancreatic or lung cancers."

New Houston platform Same Day Reels launches for on-demand content creation

In The Moment

If an event doesn't happen on Instagram, did it even really happen? In today's social media-driven age of branding and audience engagement, the answer increasingly is no.

Houston entrepreneur Karen De Amat is looking to fill the online content creation needs of companies with her new venture, Same Day Reels, which launched in early August. It will serve as a platform to connect companies and brands with talent that can help turn an event into a viral moment as it is happening.

"Events move quickly, and social media moves even faster,” said De Amat. “Same Day Reels was built to help brands capture the moment while it still matters. We are creating a more efficient way for businesses and creators to work together. Brands need content faster, and creators need more opportunities to turn their talent into real work. Same Day Reels brings those needs together.”

The company is focused on adding livestreams and concurrent short video content to "activations, launches, fundraisers, grand openings, conferences, hospitality experiences, and private celebrations." Such content can significantly increase the visibility of a product or brand according to digital marketing brands like Wyzowl, whose data found 63 percent of people in 2026 prefer to learn about new products via short video.

Packages offered by Same Day Reels will include filming, editing, and publishing content within hours of the targeted event.

De Amat says that her content creation platform will be a way to preserve the excitement of events and launches by enshrining them with immediate social media-driven memories.

“Event content is no longer just something you post after the fact,” De Amat said. “It is part of how people experience, remember and share the moment.”

Previously, De Amat is also the founder and CEO of Social Behavior, an influencer marketing company she launched from her home in 2014. It quickly garnered an array of clients and thrust De Amat into the spotlight, including numerous appearances on Fox 26's The Isiah Factor. Influencer Marketing Hub named her one of the top CEOs of influencer marketing companies in Houston in 2025.

---

This article originally appeared on CultureMap.com.

Bristol Myers Squibb to build $2.3B Houston pharma manufacturing campus

coming soon

New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. has officially named Houston as the home of its new state-of-the-art manufacturing site.

The 60,000-square-foot facility represents a $2.3 billion investment, according to a news release. It is expected to create 500 skilled jobs and will be located in Houston's Generation Park.

BMS first announced that it was considering Houston among 16 other cities for the facility in May. The new hub will manufacture small molecule, biologic and antibody-drug conjugates and is part of a $40 billion commitment to invest in the United States over five years. Construction is slated to begin next year, with the facility coming online in 2030.

"We're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life," Christopher Boerner, CEO and board chair of BMS, said in the release.

The new facility will feature a modular, multi-modal design, which will allow the company to reconfigure and add to its manufacturing capabilities over time. BMS says it expects the facility to "(grow) in scale and capability well beyond its opening configuration."

"Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” Karin Shanahan, EVP and chief supply chain and operations officer of BMS, added in the release. “This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands.”

Texas Gov. Greg Abbott shared that the state has granted BMS a $4.89 million Texas Enterprise Fund (TEF) grant for the project. TEF grants, administered by the Texas Economic Development & Tourism Office, support business relocation or expansion projects that create "new, good-paying jobs in the community and attract significant new capital investment to the state." The development is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program.

“Texas is a global hub for life sciences, where today’s innovations shape the future of healthcare,” Abbott said in a news release. “This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers.”

"Bristol Myers Squibb’s announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing,” added Greater Houston Partnership President and CEO Steve Kean.

Last fall, Eli Lilly and Co. selected Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.

View All Listings